GN-CORPORATION
26.10.2020 07:05:07 CET | Business Wire | Press release
Caucasian, Hispanic and Afro-American population, when Covid-19 infected, are prone to abnormal blood clotting, that may lead to stroke. Pregnant women and people with comorbidities are also at high risk. Higher mortality has been reported in patients, whose fasting plasma glucose is very high at the time of hospital admission with SARS-COV-2. During this unprecedented pandemic, a prophylaxis to Covid-19 in diabetic population , and strategies for Prevention of Covid-19 associated coagulopathy by consumption of Beta glucan food supplement produced by Black yeast Aureobasidium Pullulans AFO-202 strain has been published in Journal of Diabetes and Metabolic Disorders (https://doi.org/10.1007/s40200-020-00664-4 ) and Thrombosis Journal (https://doi.org/10.1186/s12959-020-00239-6 ) respectively, recommending clinical studies for its validation in Covid-19 patients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201025005031/en/
COVID-19 virus damages blood vessels, causing clot or thrombus formation resulting in stroke and disruption of the body’s blood clotting system, leading to organ damage and death. Metabolic and immune dysregulation leads to higher mortality in diabetes patients. The AFO-202 derived Nichi-Glucan has potentials to alleviate the cytokine storm, minimize coagulation disruption, and prevent complications of Covid-19 by balancing blood glucose & cholesterol, according to the authors, who have earlier published its immune enhancement and modulation capabilities to help tackle Covid-19 (https://doi.org/10.3389/fimmu.2020.01548 ). Pilot studies in Diabetic and Dyslipidemic individuals from south Asian population also have been reported (https://doi.org/10.1155/2012/895370 ).
Unique advantages: Research of Prof. Noboru Fujii on poly-thermo tolerant fungi lead to the successful culture of Aureobasidium Pullulans and Mr. Takashi Onaka (President, Sophy Inc) accomplished its industrial scale GMP production in Kochi, Japan, which was approved by Japanese health ministry as a food additive and in the market since 1996. Among several ß-Glucans produced by extraction and purification methods from sources like yeast-cell wall, Shiitake mushroom, Oats, Algae etc, Nichi Glucan is unique, being secreted as an exo-polysaccharide by AFO-202, possessing a distinct structure, water solubility, high purity, functionality and molecular weight of 30,000. Safety has been confirmed by genotoxicity, repeated and long-term administration tests. Recently, a new strain, N-163 secreted product, having advantageous characteristics to contribute to human health is undergoing studies. Nichi Glucan is available in Japan (www.nichiglucan.com ) and in India (https://www.amazon.in/dp/B08DFDX2HQ ), exported worldwide by GN Corporation.
Disclaimer: Nichi-Glucan is a food supplement, free from 25 most common allergens. It’s not a drug or curative/therapeutic agent.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201025005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samos Energy Acquisition Corporation Announces Pricing of Initial Public Offering10.7.2026 15:32:00 CEST | Press release
Samos Energy Acquisition Corporation (the “Company”) announced today the pricing of its initial public offering (“IPO”) of 20,000,000 units at a price of $10.00 per unit. The units will be listed on the New York Stock Exchange (the “NYSE”) and trade under the ticker symbol “SAMO.U” beginning on July 10, 2026. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one of the Company’s Class A ordinary shares at an exercise price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the NYSE under the symbols “SAMO” and “SAMO.WS,” respectively. Cantor Fitzgerald & Co. is acting as the sole book running manager for the proposed offering. The Company has granted the underwriter a 45-day option to purchase up to an additional 3,000,000 units at the IPO price. The public offering is being made
Onera hPSG® Wins Prestigious Red Dot Product Design Award10.7.2026 15:00:00 CEST | Press release
Onera Health's patch-based home polysomnography solution, Onera hPSG®, was awarded the renowned ‘Red Dot Award: Product Design 2026’ in recognition of the sensors’ innovative design, advanced functionality, and user-centric engineering. Onera Health, a leader in transforming sleep medicine, announces that its innovative product, Onera hPSG®, has been honoured with the prestigious Red Dot Product Design Award for 2026. This international recognition celebrates exceptional design quality and underscores Onera Health's commitment to excellence, creativity, and patient-centric innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260710266668/en/ Onera Health's patch-based home polysomnography solution, Onera hPSG®, wins Prestigious Red Dot Product Design Award 2026. The Red Dot Award, one of the most sought-after seals of quality for good design, attracted thousands of entries from around the globe. Onera hPSG® stood out f
teamLab Biovortex Kyoto Welcomes Over 1 Million Visitors within 9 Months of Opening10.7.2026 09:00:00 CEST | Press release
teamLab Biovortex Kyoto has welcomed over 1 million visitors as of July 6, 2026, 9 months after its grand opening. (*1) These visitors arrived from more than 150 countries and regions. International visitors account for approximately 42% of the total. Many of these international visitors travel from distant countries and regions, including the United States, Australia, Canada, the United Kingdom, and Germany. Approximately 30% of these international visitors purchase their tickets at least 30 days in advance. teamLab Biovortex Kyoto is teamLab's largest museum in Japan, with an average visitor stay of over two and a half hours. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709913938/en/ teamLab Biovortex Kyoto Welcomes Over 1 Million Visitors within 9 Months of Opening *1 According to ticket purchase data from the official teamLab Biovortex Kyoto website (survey period: October 7, 2025 – July 6, 2026) Visitors Comment (M
Robbyant Launches LingBot-VA 2.0 Built Natively for Embodied AI and Physical World Control10.7.2026 08:48:00 CEST | Press release
Robbyant, an embodied AI company within Ant Group, today announced the release of LingBot-VA 2.0, the industry’s first embodied-native video-action world model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709654440/en/ A robot powered by LingBot-VA 2.0 engages in a real-time tabletop air hockey match with a human This release marks a key transition in robotics foundation models, shifting from repurposing digital world models to designing them natively for the physical world. Instead of relying on fine-tuned digital content generation models, LingBot-VA 2.0 is built from scratch to meet the original demands of dynamic modeling, causal prediction, and real-time execution in physical environments. Integrating world models with embodied AI has been one of the major focuses of the AI industry. However, most mainstream approaches rely on video generation models designed for digital content, which are then fine-tuned for robo
SureWerx Appoints Erik Pertot as VP/GM SureWerx EMEA10.7.2026 08:00:00 CEST | Press release
Experienced global PPE leader to strengthen portfolio strategy, operational execution, and growth across SureWerx’s international platform SureWerx, a leading global manufacturer of personal protective equipment, safety products, tools and equipment solutions, today announced the appointment of Erik Pertot as VP/GM SureWerx EMEA. Pertot will report directly to CEO Scott Dowell and will lead growth, manufacturing and M&A activities in Europe across the company’s global portfolio. Erik joins SureWerx with more than 20 years of international leadership experience across engineering, quality, marketing, sales, international supply chain, product management, and general management. He brings deep expertise in the personal protective equipment industry, with a track record of leading complex, compliance-critical programs, managing business transitions, and driving growth across multinational environments. Most recently, Pertot served as Global General Manager for Footwear and Fall Protection
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
